Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported a phase 3 trial of its lead gene therapy VB-111 for ovarian cancer failed a pivotal trial.
In the OVAL study, VB-111 – also known as ofranergene obadenovec or ofra-vec – was unable to show an improvement in progression-free survival (PFS) or overall survival (OS) in patients with platinum-resistant ovarian cancer.
